Serum autoantibodies are frequently detected in patients with chronic HCV infection, reflecting the wide spectrum of immune reactions related to this virus. In the present study, a novel autoantibody to cytoplasmic rods and rings (RR) in chronic HCV patients was characterized.
Methods
Sera from 75 previously untreated HCV patients were investigated by indirect immunofluorescence using HEp-2 cell substrate before and during pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. HEp-2 cells were cultured and fixed either following standard protocols or with the addition of RBV in culture medium.
Results
In 15 out of 75 (20%) patients, analysis revealed the presence of antibodies to rod-like cytoplasmic structures ranging approximately 3–10 mm in length and rings approximately 2–5 μm in diameter. These RR structures became detectable in >95% of cells after addition of RBV in culture medium, whereas they were absent in untreated cells. Anti-RR antibodies were found in sera collected during PEG-IFN/RBV treatment only, but never detected before antiviral therapy nor in control groups. More importantly, these anti-RR antibodies were more often detected in non-responder/relapsers than in responder patients (33% versus 11%; P-value =0.037).
Conclusions
An RBV-induced autoantibody was identified to a new cytoplasmic autoantigenic structure developed in HCV patients after PEG-IFN/RBV and this same structure can be induced by RBV in in vitro culture. Owing to the onset of anti-RR antibodies in PEG-IFN/RBV-treated patients and their association with a treatment failure, studies are deemed necessary to clarify whether anti-RR plays a role in the response to PEG-IFN/RBV therapy.
References
1.
AbuafN., LunelF., GiralP.Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol1993; 18: 359–364.
2.
CassaniF., CataletaM., ValentiniP.Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology1997; 26: 561–566.
3.
CliffordB.D., DonahueD., SmithL.High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology1995; 21: 613–619.
4.
CoviniG., von MuhlenC.A., PacchettiS.Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol1997; 26: 1255–1265.
5.
FriedM.W., DragueskuJ.O., ShindoM.Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci1993; 38: 631–636.
6.
LenziM., BellentaniS., SaccoccioG.Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut1999; 45: 435–441.
7.
LenziM., JohnsonP.J., McFarlaneI.G.Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet1991; 338: 277–280.
8.
PreziatiD., La RosaL., CoviniG.Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol1995; 132: 587–593.
9.
TranA., QuarantaJ.F., BenzakenS.High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology1993; 18: 253–257.
10.
WilliamsM.J., LawsonA., NealK.R.Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat2009; 16: 325–331.
11.
MaeckerH.T., DoM.S., LevyS.CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc Natl Acad Sci U S A1998; 95: 2458–2462.
12.
PileriP., UematsuY., CampagnoliS.Binding of hepatitis C virus to CD81. Science1998; 282: 938–941.
13.
GregorioG.V., ChoudhuriK., MaY.Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol2003; 133: 404–413.
14.
KammerA.R., van der BurgS.H., GrabscheidB.Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med1999; 190: 169–176.
15.
SuttiS., VidaliM., MombelloC.Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic hepatitis C: possible role for molecular mimicry. J Hepatol2010; 53: 431–438.
16.
YamamotoA.M., CresteilD., BonifaceO.Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol1993; 23: 1105–1111.
17.
DalekosG.N., WedemeyerH., Obermayer-StraubP.Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol1999; 30: 366–375.
18.
FabbriC., JaboliM.F., GiovanelliS.Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol2003; 9: 1487–1490.
19.
FabrisP., BetterleC., FloreaniA.Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet1992; 340: 548.
20.
FabrisP., BetterleC., GreggioN.A.Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol1998; 28: 514–517.
21.
García-BueyL., Garcia-MonzonC., RodriguezS.Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology1995; 108: 1770–1777.
22.
ImagawaA., ItohN., HanafusaT.Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis. Diabetologia1996; 39: 126.
23.
PapoT., MarcellinP., BernuauJ.Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med1992; 116: 51–53.
24.
ShindoM., Di BisceglieA.M., HoofnagleJ.H.Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology1992; 102: 1406–1408.
25.
TodrosL., SaraccoG., DurazzoM.Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology1995; 22: 1374–1378.
26.
WescheB., JaeckelE., TrautweinC.Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut2001; 48: 378–383.
27.
BaronS., TyringS.K., FleischmannW.R.Jr.. The interferons. Mechanisms of action and clinical applications. JAMA1991; 266: 1375–1383.
28.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
29.
KogureT., UenoY., FukushimaK.Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol2007; 13: 4394–4397.
30.
Narciso-SchiavonJ.L., FreireF.C., SuarezM.M.Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?Eur J Gastroenterol Hepatol2009; 21: 440–446.
31.
FerriS., MuratoriL., QuarnetiC.Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. J Hepatol2009; 50: 1093–1101.
32.
GatselisN.K., GeorgiadouS.P., KoukoulisG.K.Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther2006; 24: 1563–1573.
33.
WasmuthH.E., StolteC., GeierA.The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis2004; 4: 4.
34.
YeeL.J., KelleherP., GoldinR.D.Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat2004; 11: 459–464.
35.
DienstagJ.L., McHutchisonJ.G.American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology2006; 130: 231–264.
36.
AlvarezF., BergP.A., BianchiF.B.International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol1999; 31: 929–938.
37.
JakymiwA., PauleyK.M., LiS.The role of GW/P-bodies in RNA processing and silencing. J Cell Sci2007; 120: 1317–1323.
38.
HombergJ.C., AndreC., AbuafN.A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol1984; 55: 561–570.
39.
MatsudaJ., SaitohN., GotohM.High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol1995; 90: 1138–1141.
40.
StroffoliniT., ColloredoG., GaetaG.B.Does an ‘autoimmune’ profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. J Viral Hepat2004; 11: 257–262.
41.
TanE.M.Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol1989; 44: 93–151.
42.
TanE.M.Autoantibodies in pathology and cell biology. Cell1991; 67: 841–842.
